Bearish
🤖 85%
Trump Renews Tariff Threat on Indian Drugmakers, Dr. Reddy’s Slides
Dr. Reddy’s Laboratories fell 4.2% as the renewed US tariff threat directly threatens its largest revenue source. The company derives over 40% of income from the US generics market, where its pricing advantage would evaporate under new duties. The move signals margin compression and potential lost contracts to domestic US or other non‑tariffed competitors.
Catalysts
- ▼ Trump administration explicitly renewed tariff threat on Indian generic drug imports
Risk Factors
- ▲ Congressional pushback or pharma lobby could delay tariffs
- ▲ Dr. Reddy’s could accelerate US manufacturing plans to circumvent duties
▼ Show FAQ (2) ▲ Hide FAQ
How exposed is Dr. Reddy’s to US tariffs?
The US accounts for roughly 42% of Dr. Reddy’s revenue. A 25% tariff would slash ex‑US margins by 15–20%, making many generic launches unprofitable and forcing a re‑evaluation of its US pipeline.
Will this impact Dr. Reddy’s earnings this quarter?
Short‑term impact is likely sentiment‑driven, but if tariffs are imposed, the company’s FY2027 forecasts could be cut by 10–15% due to lost US volumes and higher pricing pressure.